Repligen Corporation
General ticker "RGEN" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $7.7B (TTM average)
Repligen Corporation follows the US Stock Market performance with the rate: 33.0%.
Estimated limits based on current volatility of 1.8%: low 164.34$, high 170.23$
Factors to consider:
- Total employees count: 1778 (-0.3%) as of 2024
- Top business risk factors: Market competition, Operational and conduct risks, Climate change and natural disasters, Liquidity and credit risks, Integration challenges
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [94.70$, 160.35$]
- 2025-12-31 to 2026-12-31 estimated range: [87.24$, 150.42$]
Financial Metrics affecting the RGEN estimates:
- Negative: with PPE of 98.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: 0.33 < Operating cash flow per share per price, % of 2.15
- Positive: Interest expense per share per price, % of 0.25 <= 0.79
- Positive: -2.95 < Return on assets ratio (scaled to [-100,100]) of -0.89
- Positive: Inventory ratio change, % of -5.68 <= -0.75
- Positive: -8.75 < Industry operating profit margin (median), % of -7.19
Short-term RGEN quotes
Long-term RGEN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $801.54MM | $632.36MM | $634.44MM |
| Operating Expenses | $576.87MM | $584.66MM | $669.55MM |
| Operating Income | $224.67MM | $47.70MM | $-35.11MM |
| Non-Operating Income | $-5.53MM | $9.00MM | $8.08MM |
| Interest Expense | $1.16MM | $2.50MM | $20.73MM |
| R&D Expense | $43.94MM | $42.72MM | $43.20MM |
| Income(Loss) | $219.14MM | $56.71MM | $-27.04MM |
| Taxes | $33.18MM | $21.11MM | $-1.52MM |
| Profit(Loss)* | $185.96MM | $29.61MM | $-25.51MM |
| Stockholders Equity | $1,910.70MM | $1,964.85MM | $1,972.72MM |
| Inventory | $238.28MM | $202.32MM | $142.96MM |
| Assets | $2,531.60MM | $2,831.18MM | $2,829.67MM |
| Operating Cash Flow | $172.08MM | $113.92MM | $175.39MM |
| Capital expenditure | $133.35MM | $38.99MM | $32.91MM |
| Investing Cash Flow | $-233.24MM | $-123.28MM | $-86.38MM |
| Financing Cash Flow | $-13.34MM | $248.96MM | $-82.90MM |
| Earnings Per Share** | $3.35 | $0.53 | $-0.46 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.